Amnestic mild cognitive impairment )aMCI( is a condition characterized by mild deficits in episodic and semantic memory and learning. The conversion rate of aMCI to Alzheimer disease )AD( is significantly higher in aMCI than in the general population. The aim of this study is to examine whether aMCI is a valid diagnostic category or whether aMCI comprises different subgroups based on cognitive functions. We recruited 60 aMCI patients, 60 with AD and 61 healthy controls who completed neuropsychological tests of the Consortium to Establish a Registry for Alzheimer's Disease )CERAD-NP( and biomarkers including serum anion gap )AGAP(. Principal component analysis, support vector machine and Soft Independent Modeling of Class Analogy )SIMCA( showed that AD patients and controls were highly significantly discrimanted from each other, while patients with aMCI overlap considerably with normal controls. SIMCA showed that 68.3% of the aMCI patients were assigned to the control class )named: aMCI-HC(, 15% to AD )aMCI-AD(, while 16.6% did not belong to either class )aMCIstrangers(. aMCI-HC subjects showed sings of very mild cognitive decline and impaired recall.
Introduction
Memory disorders are common complaints that are of great concern among senior citizens around the world. Alzheimer's disease )AD( is the most common cause of dementia and accounts for around 64-90 % of the neuropathological findings in all subjects with dementia )1(. AD is a progressive neuroinflammatory and neurodegenerative disorder of the brain )2, 3( and patients with that disease show a gradual decline in learning, attention, memory, executive functions and language causing impairments in social interactions and difficulties in carrying out activities of daily living )ADL( )3(. Hence, the aim of the present study is to examine whether aMCI is a distinct diagnostic class based on cognitive function as assessed with the CERAD-NP or comprises subgroups with a different cognitive profile.
Subjects and Methods

Participants
In the current study we recruited 181 participants of Thai nationality, both sexes and age ranging from 55 to 90 years. All subjects with memory impairments, including aMCI and AD, were recruited at the Dementia clinic, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. Healthy control subjects were community healthy aging senior club members or senior Red Cross volunteers, King Chulalongkorn Memorial Hospital. All controls and AD/aMCI patients were recruited from the same catchment area, namely Pathumwan district, Bangkok province, Thailand.
The AD diagnosis was made using criteria of the National Institute of Neurological and Communication Disorders and Stroke/AD and Related Disorders Association )NINCDS-ADRDA( )41( In addition, we included only patients with a( a score on the Thai Clinical Dementia Rating Scale )CDR( between 1 and 2; b( a score on the Thai Mini-Mental State Examination )MMSE-Thai( )42( between 10 and 23; and c( impaired ADL as assessed using the Blessed Dementia Scale )43, 44(. aMCI patients presented with subjective memory complaints and were diagnosed using Petersen's Criteria. )4(. Subjective memory complaints were assessed using the question "do you feel that your memory is becoming worse" )14, 15(. Additional inclusion criteria for aMCI patients were a Thai MMSE score > 23 and a CDR score equaling 0.5. Controls were only included if they did not show subjective memory complaints and when they had a CDR score of 0 and a Thai MMSE > 23. Consequently, subjects were divided into three study groups, namely 60 AD, 60 aMCI and 61 normal controls.
We considered the following exclusion criteria for aMCI and AD patients and controls: a( medical disorders such as chronic obstructive pulmonary disease, vitamin B12 deficiency, hypothyroidism, severe heart disease )functional class II or more(, cancer and chronic kidney All participants and all guardians of patients with MCI and AD provided written informed consent prior to participation in this study. The study was conducted according to Thai and international ethics and privacy laws. Approval for the study was obtained from the
Methods
All patients were assessed by a senior psychiatrist or neurologist who are specialized in dementia research. They used a semi-structured interview to score clinical history and they performed physical and neurological examinations. The CDR was used to estimate dementia staging and to confirm AD diagnosis )45(. One clinical research psychologist specialized in dementia scored all participants using the CERAD-NP in a validated translation for use in a Thai population )27, 35(. She was blinded from the CDR and clinical diagnosis. We scored 6 neuropsychological subdomains, namely the Modified Boston Naming Test )BNT(, to probe visual naming and confrontational word retrieval; Verbal fluency Test )VFT(, to probe fluency and semantic memory; the Word List Memory )WLM(, to probe verbal episodic memory or immediate working memory; the Word List Recall )WLRecall( to probe delayed recall and verbal episodic memory recall, the Word List Recognition )WLRecognition( to probe verbal episodic memory-discriminability; and the Constructional Praxis test, to probe visuo-constructive abilities )18, 19(. The total sum on the CERAD-NP was computed. In addition, the same research psychologist measured the Mini-Mental State Examination )MMSE( in a validated Thai translation )MMSE Thai 2002, MMSE( )42, 46(. This test probes concentration, orientation, language, memory and praxis. The psychologist also measured the CERAD Blessed Dementia Scale )BDS(, to probe Activities of Daily Living )ADL(; the Short Blessed Test )SBT(, to assess memory and concentration; and the CERAD Behavior Rating Scale for Dementia )BRSD( including depressive symptoms, inertia, vegetative symptoms, irritability/aggression, behavioral dysregulation and psychotic symptoms subscale scores. The total BRSD score was computed.
Axis-1 DSM-IV-TR criteria were used to make the diagnosis of axis 1 psychiatric diagnosis and exclude subjects accordingly.
In addition, we performed MRI brain scans )1.5T MRI scans( and collected blood in all participants to assay thyroid function test )free T3 and T4, TSH(, liver function tests )ALT, AST(, serum B12 levels, complete blood count, lipid profile including total cholesterol, high density lipoprotein and low density lipoprotein cholesterol, kidney function tests including blood urea nitrogen and creatinine kinase, and serum uric acid. These blood test were performed in the Central Laboratory, King Chulalongkorn Memorial Hospital, an accredited laboratory conforming to ISO 15189 standards.
Assays
Fasting blood was sampled at 8.00 a.m from healthy controls and aMCI/AD patients for the assay of ApoE genotypes and selected biochemical measurements. This study used 3 mL clotted blood )serum(, centrifuged at 1,000 g during 5 minutes and used the Architect C8000 )Abbott Laboratories, Abbott Park, Illinois, USA( to assay the following parameters: blood electrolytes )Sodium, Potassium and Chloride( measured by indirect ion selective electrode )CV 1.3%, 1.4% and 1.2%, respectively( and used to compute anion gap. Blood carbon dioxide was assayed using the PEP carboxylase method with a CV of 5.9%. Plasma glucose levels were measured by Hexakinase/ G-6-PDH technique with inter-assay coefficients of variability )CV( of 2.0%. in all participants combined in order to display the distribution of the diagnostic classes in the multivariate space whereby the diagnostic groups are differentiated by marker colors and shapes.
We used a standard deviation weighting process and a 20-fold cross-validation scheme. We also Results.
GLM analysis Table 1 shows the socio-demographic data as well as CERAD measurements in normal controls, AD and aMCI patients. Figure 1 shows the mean )SE( values of the z scores of the CERAD tests and the total CERAD score in aMCI and AD patients and healthy controls.
Multivariate GLM analysis adjusted for age, sex and education shows that diagnosis has a highly significant effect )partial eta squared effect size=0.529( on the CERAD tests )F=31.81, df=12/340 p<0.001(, while tests for between-subject effects show highly significant effects on all tests scores )with effect sizes between 1.728 for WLRecall and 1.161 for constructional praxis(.
Pairwise comparisons show significant differences in VFT, BNT, WLM, WLRecall and CERAD total between the three subgroups and that all tests scores significantly decreased from controls  aMCI  AD. Constructional praxis, and WLRecognition were lower in AD than in controls and aMCI, without any differences between controls and aMCI.
Principal component analysis Figure 2 shows a first PC plot )PC1 vs PC2( performed on controls and AD patients only. Both PCs explain together 88% of the variance and therefore the loadings on both PCs can be interpreted accurately. This figure shows that AD patients cluster at the right-hand side of the PC plot and that controls cluster at the left-hand side, while there is a large street )boundaries( between both groups. Figure 3 shows the same PC plot but now with inclusion of the aMCI patients. It can be seen that the latter fill in the gap between the controls and aMCI patients. The distribution of the subjects in this 2D plot indicates a continuum of cognitive dysfunction from controls to AD patients. Figure 4 shows the correlation loadings of the CERAD test scores on both PCs indicating that VFT, WLM, WLRecall, WLrecognition and CERAD total strongly contribute to the differentiation of the classes along PC1, while constructional praxis and BNT contribute to the variability on PC1 but also PC2.
Support Vector Machine In order to build a SIMCA model separating AD from HC, we used a training set comprising 50% of the AD and 50% of the control subjects. The test set comprised the remaining 50% controls and AD patients, whereas all aMCI cases were subsequently projected into the AD and HC PCA models. When building the two PCA models surrounding the HC and AD classes we deleted two healthy controls and 1 AD patient from the PCA models )as statistical outliers( and we modeled both classes using 6 PCs. The model-to-model distance was 92.68 indicating a very accurate discrimination of both classes, while all CERAD variables showed significant modeling power for AD and HC. Figure 6 shows the discrimination power of the CERAD features in separating AD from controls in descending order: WL Recall, WLRecognition, CERAD total, BNT, VFT, praxis and WLM. Figure 7 shows the Si/S0 versus Hi plots and the distances of the subjects in the AD and control calibration sets to the AD PCA model )in the lefthand corner of the plot(. We found that all AD patients )displayed as red dots(, except two outsiders, were correctly classified as belonging to the AD class, while all controls )displayed as blue squares( were discriminated from the AD patients. As such, the sensitivity of the SIMCA model in authenticating AD subjects is 93.3% with a specificity of 100%. Figure 8 shows the Si/S0 versus Hi plots and the distances of the calibration subjects to the PCs surrounding the controls. This plot shows that all controls, except one )see blue squares(, were authenticated as belonging to the claimed HC class, while all AD patients )red dots( were classified as outsiders.
Consequently, we have projected the 60 aMCI cases to both PCA models whereby aMCI patients are displayed as green triangles in figures 8 and 9. The results show that 9 aMCI cases )named aMCI-AD( intruded the critical limits of the AD class, while as many as 41 aMCI patients )named aMCI-HC( intruded into the HC class )see Figure 9 (, while the classification results
show that 10 aMCI patients )named: aMCI-strangers( did not belong to either the AD or HC classes. We have also rerun the analyses with two other sets of input variables, namely the 7 CERAD test scores combined with the Blessed ADL score or with the MMSE score. Those SIMCA analyses yielded similar results. Figure 9 shows the CERAD features of the 3 aMCI subclasses delineated by SIMCA as compared with controls and AD. Table 2 shows the socio-demographic data and CERAD tests results in the three aMCI subclasses as compared with AD and controls (see table 1 for mean values). The profile of the 41 aMCI-HC subjects showed a CERAD profile quite similar to that of controls. Moreover, multivariate GLM analyses followed by tests-for between subject effects and pairwise comparisons showed only a few mild differences between HC and aMCI-HC patients, namely WLRecall )p=0.001( and CERAD total score )p=0.004(, while all other tests did not significantly differ between both groups. In addition, there were no significant differences in age, sex ratio and education between both groups. The group of the 10 aMCI-strangers showed a peculiar profile characterized by lower education, VFT and constructional praxis, while WLRecognition and WLRecall were better preserved. The 9 aMCI-AD subjects showed a profile characterized by lowered scores on all CERAD tests and thus resembles that of AD, although the severity of the cognitive features is significantly less pronounced than in AD. In order to detect a simpler decision rule based on one CERAD-NP test score rather than the SIMCA model, we have performed binary regression analyses with both aMCI-strangers + aMCI-AD groups versus AD as dependent variables and the CERAD-NP tests as explanatory variables. Neverthless, we could not find that one or more CERAD-NP tests reliably predicted those diagnoses with an accuracy > 87%. Figure 10 shows the BRSD items, BRSD total, Blessed ADL, SBT and MMSE scores in the 5 study groups and shows that those scores are significantly more disturbed in AD patients than in controls and those allocated to the three aMCI subgroups. Furthermore, no significant differences in any of these rating scale score could be established between the four non-AD subgroups. Figure 11 shows the measurements of FBG, HCO3-, AGAP and AIP in the three new aMCI groups (compared with controls and AD patients, see values in Table 1 ). Univariate GLM analyses showed significantly lower HCO3-)F=7.29, df=1/177, p=0.008( and higher AGAP )F=7.46, df=1/176, p=0.007( levels in aMCI-AD patients as compared with the other subjects.
Discussion
The first major finding of this study is that, using SIMCA, PCA and SVM, patients with AD are highly significantly separated from healthy controls using CERAD-NP tests and that aMCI is an intermediate group considerably overlapping with healthy controls and less with AD.
Our SIMCA results show that the top-3 most dominant features of AD are lowered scores on WLRecall, WLRecognition and BNT. As reviewed in the introduction, there are some studies examining the cognitive profile of AD versus controls showing that the CERAD total score may be used to discriminate AD patients from controls with an area under the receiving operating curve )ROC( of 0. These figures of merit do not allow a predictive classification )47( of aMCI versus controls using the CERAD-NP scores. All in all, these results show that aMCI cannot be successfully discriminated from healthy controls using CERAD-NP test results as input variables.
In our study using a combination of different CERAD-NP tests we found that aMCI and AD were relatively well separated using SVM )validation accuracy: 92.5%( and SIMCA )validation accuracy of 89.17%(. Using SIMCA we found that the top-3 features separating AD from aMCI are in descending order: WLRecall, WLRecognition and WLM, indicating that
WLRecall and WLRecognition are the most adequate features to discriminate AD from controls and aMCI patients. In the Seo et al. )22( study, the separation of MCI versus AD using the CERAD total score yielded an area under the ROC curve of 1.86. Nevertheless, these figures of merit do not allow the SIMCA, SVM or ROC models to be used for prediction purposes )47(.
Based on the accuracy of both SVM )100%( and SIMCA )97.2%( separating AD from controls we concluded that those models may be employed to classify unknown cases into AD or the control class. Nevertheless, SVM operates with the assumption that all cases should belong to one of the pre-specified classes and therefore SVM forces aMCI subjects to be classified as AD cases or controls )47(. Accordingly, SVM methods miss precision because this method cannot identify cases that belong to two classes )hybrids( or do not belong to any predefined class )strangers( )47(. In this regard, SIMCA improves precision of the identification process because this technique allows to authenticate AD patients as belonging to the presumed AD class, and to identify unknown subjects as aliens, hybrids or strangers )47(. Therefore, our validated SIMCA models built using the control and AD classes may be used to identify aMCI patients.
The second major finding of our study is that aMCI as diagnosed with Petersen' criteria )4( consists of three distinct subgroups. Using CERAD-NP scores, SIMCA assigned 68.3% of the patients to the control class )named: aMCI-HC(, 15% to the AD class )named: aMCI-AD(, while 16.6% did not belong to either class )aMCI-strangers(. It should be underscored that all our aMCI subjects scored 1.5 on the CDR Staging Dementia Instrument indicating that they suffered from very mild dementia with mild memory impairments, slight impairments in cummunity affairs without dysfunctions in personal care )45(. As such, an assignment of aMCI patients to the control or AD class indicates that their cognitive profile )but not behavioral symptoms or ADL( is quite similar to that of these target groups, but does not allow to conclude that these subjects may be diagnosed as AD or controls.
The main characteristic of aMCI-HC subjects was a lowered WLRecall score but the other neurocognitive CERAD probes were quite similar to that of normal controls with a difference in total CERAD score of only 1.276 SDs. Therefore, these individuals could be diagnosed as SMI, because they show subjective memory complaints and a deficit in delayed recall )14, 15(. According to these authors, SMI is an at-risk condition to develop AD )14, 15(, although this effect may be confined to SMI with self-reported concerns )15(. In our study subjective memory impairment was one of the criteria to diagnose aMCI although we did not measure "self-reported concerns". By inference our aMCI-HC subgroup cannot be considered to constitute an at-risk group to develop AD.
The two other aMCI subgroups defined by SIMCA showed a much lower CERAD total score that differed cosiderably from that of controls, namely 1.911 SDs for aMCI-strangers and 1.16 SDs for the aMCI-AD cases. Increasing levels of cognitive impairment in MCI are at-risk factors of AD )15, 49(, indicating that these two SIMCA subgroups may be at increased risk to the develop AD. The main characteristics of the aMCI-stranger subgroup were significantly lower scores on VFT, praxis and naming. As such this subgroup shows more selective deficits in language and fluency, semantic memory and praxis. It could be that this subgroup is a prodromal stage of semantic dementia )50(, which is accompanied by loss of fluent speech and poor category fluency without loss of episodic memory. The second subgroup )aMCI-AD( is clearly a dementia prodrome as the constellation of cognitive dysfuctions observed in these patients resembles that of AD, although with less severity. Once behavioral symptoms develop or personal care deteriorates these aMCI-AD subjects will be diagnosed as AD.
Although we did not measure the Global Deterioration Scale )GDS( for Assessment of Primary Degenerative Dementia )51( it is interesting to apply this staging scale to our SIMCA aMCI subgroups. Thus, the aMCI-HC patients probably belong to GDS stage 2 or very mild cognitive decline, while aMCI-strangers probably belong to GDS stage 3 or mild cognitive decline. Subjects allocated to the aMCI-AD subgroup belong to the transition zone from stage 3 to stage 4 )moderate cognitive decline( which is an early stage dementia.
Our SIMCA findings may question the definitions of early CMI )EMCI( [a condition characterized by cognitive impairments on a standardized test, which are 1.0-1.5 SDs lower than the normative mean] and late MCI )LMCI( [a condition characterized by cognitive impairments on a standardized test, which are > 1.5 SDs lower than the normative mean] )52(. In fact, while our aMCI-AD patients are allocated to the AD group based on a similar cognitive profile they show impairments on MMSE, SBT and CERAD total of around 1.2 SDs, but not 1.5 SDs, lower than the normative mean. In the current study we detected that a combination of different CERAD-NP features in a SIMCA model is a very adequate method to define a subgroup )aMCI-AD( of patients with a cognitive profile that is reminiscent of AD but cannot be classified as AD because ADL is still intact. Future prospective research in early AD recognition studies should therefore compare the predictive value of our SIMCA decision rule versus the case definitions of SMI, ECMI and LCMI as predictors of AD in larger study groups.
The third major finding of this study is that the SIMCA-derived aMCI-AD subgroup was externally validated by highly increased AGAP and lowered HCO3-values )but not ApoE4, In conclusion, in the current study we have delineated a SIMCA model that can be used clinically to classify subjects with aMCI into subgroups, which appear to indicate different stages of cognitive decline. The first subgroup are subjects with a very mild cognitive decline are differentiated from controls by SMI and lowered delayed recall. The second subgroup displays signs of mild cognitive decline with lowered fluency and naming as important features and these subjects may be at an increased risk to develop dementia. The third subgroup comprises patients in the transition zone from moderate cognitive decline to early-stage dementia and, therefore, these patients show a dementia prodrome. 
